FibroGen, Inc. (NASDAQ:FGEN) Short Interest Down 5.2% in January

FibroGen, Inc. (NASDAQ:FGEN) was the target of a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 2,910,000 shares, a decrease of 5.2% from the January 15th total of 3,070,000 shares. Based on an average trading volume of 1,250,000 shares, the short-interest ratio is presently 2.3 days.

FibroGen Stock Up 6.5 %

FGEN opened at $0.55 on Tuesday. The firm has a market cap of $55.88 million, a P/E ratio of -0.45 and a beta of 0.75. The business’s fifty day simple moving average is $0.50 and its 200 day simple moving average is $0.42. FibroGen has a 52 week low of $0.18 and a 52 week high of $2.80.

Analyst Upgrades and Downgrades

A number of analysts have commented on FGEN shares. William Blair reiterated a “market perform” rating on shares of FibroGen in a research report on Wednesday, November 13th. HC Wainwright upgraded shares of FibroGen to a “strong-buy” rating in a research report on Tuesday, December 17th. Finally, StockNews.com started coverage on shares of FibroGen in a research report on Thursday, February 13th. They issued a “hold” rating on the stock.

Institutional Investors Weigh In On FibroGen

A number of hedge funds and other institutional investors have recently modified their holdings of FGEN. Velan Capital Investment Management LP acquired a new stake in FibroGen during the fourth quarter worth approximately $42,000. Squarepoint Ops LLC purchased a new stake in shares of FibroGen in the fourth quarter valued at $205,000. Two Sigma Investments LP increased its stake in FibroGen by 19.6% in the fourth quarter. Two Sigma Investments LP now owns 604,421 shares of the biopharmaceutical company’s stock valued at $320,000 after purchasing an additional 98,888 shares during the last quarter. Two Sigma Advisers LP increased its stake in FibroGen by 18.3% in the fourth quarter. Two Sigma Advisers LP now owns 878,400 shares of the biopharmaceutical company’s stock valued at $465,000 after purchasing an additional 135,600 shares during the last quarter. Finally, Two Sigma Securities LLC purchased a new position in FibroGen during the fourth quarter worth about $27,000. 72.71% of the stock is currently owned by hedge funds and other institutional investors.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.